Last reviewed · How we verify
Nitro-Bid 2 % Topical Ointment
Nitroglycerine is a nitrate vasodilator that releases nitric oxide to relax vascular smooth muscle and improve blood flow.
Nitroglycerine is a nitrate vasodilator that releases nitric oxide to relax vascular smooth muscle and improve blood flow. Used for Angina pectoris (prophylaxis and acute relief), Congestive heart failure.
At a glance
| Generic name | Nitro-Bid 2 % Topical Ointment |
|---|---|
| Sponsor | University of Virginia |
| Drug class | Nitrate vasodilator |
| Target | Guanylate cyclase (via nitric oxide) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Nitroglycerine undergoes enzymatic bioconversion to produce nitric oxide, which activates guanylate cyclase and increases cGMP levels in vascular smooth muscle cells. This leads to vasodilation of both arteries and veins, reducing preload and afterload on the heart and improving coronary blood flow. The topical ointment formulation provides sustained, transdermal delivery for prolonged therapeutic effect.
Approved indications
- Angina pectoris (prophylaxis and acute relief)
- Congestive heart failure
Common side effects
- Headache
- Dizziness
- Hypotension
- Tachycardia
- Contact dermatitis (at application site)
Key clinical trials
- Nitroglycerin Ointment for Pain Relief After Endoscopic Hemorrhoid Band Ligation (PHASE4)
- Enhancing Wound Perfusion in High-Risk Lower Extremity Orthopaedic Surgery: A Study on Nitropaste Using Intraoperative SPY Imaging. (PHASE1)
- Effect of Nitropaste in Chest Masculinizing Surgery (PHASE4)
- Comparison of Injections of Botulinum Toxin and Topical Nitroglycerin Ointment for the Treatment of Chronic Anal Fissure (NA)
- Safety and Tolerability of Nitro for Radial Artery Dilation (EARLY_PHASE1)
- Ointment Therapy and Prevention of Cannulation-Induced Superficial Phlebitis (PHASE1, PHASE2)
- Topical Nitroglycerin To Prevent Radial Artery Occlusion After Transradial Access: NTP-RAO Trial (PHASE3)
- Screening for Colorectal Cancer in Average and High Risk Population (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nitro-Bid 2 % Topical Ointment CI brief — competitive landscape report
- Nitro-Bid 2 % Topical Ointment updates RSS · CI watch RSS
- University of Virginia portfolio CI